Cargando…
Circulating tumor DNA analysis as a real-time method for monitoring tumor burden in melanoma patients undergoing treatment with immune checkpoint blockade
BACKGROUND: Assessment of therapeutic activity of drugs blocking immune checkpoints such as CTLA-4 and PD-1/PD-L1 can be challenging, as tumors may seem to enlarge or appear anew before regressing, due to intratumoral inflammation. We assessed whether circulating tumor DNA (ctDNA) levels could serve...
Autores principales: | Lipson, Evan J, Velculescu, Victor E, Pritchard, Theresa S, Sausen, Mark, Pardoll, Drew M, Topalian, Suzanne L, Diaz, Luis A |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4267741/ https://www.ncbi.nlm.nih.gov/pubmed/25516806 http://dx.doi.org/10.1186/s40425-014-0042-0 |
Ejemplares similares
-
Integrative Tumor and Immune Cell Multi-omic Analyses Predict Response to Immune Checkpoint Blockade in Melanoma
por: Anagnostou, Valsamo, et al.
Publicado: (2020) -
Mechanisms regulating PD-L1 expression on tumor and immune cells
por: Chen, Shuming, et al.
Publicado: (2019) -
Insights into therapeutic resistance from whole-genome analyses of circulating tumor DNA
por: Diaz, Luis A., et al.
Publicado: (2013) -
Safety and immunologic correlates of Melanoma GVAX, a GM-CSF secreting allogeneic melanoma cell vaccine administered in the adjuvant setting
por: Lipson, Evan J, et al.
Publicado: (2015) -
Clonal dynamics of circulating tumor DNA during immune checkpoint blockade therapy for melanoma
por: Takai, Erina, et al.
Publicado: (2021)